Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 15, Issue 5, Pages 574
Publisher
MDPI AG
Online
2022-05-04
DOI
10.3390/ph15050574
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion
- (2021) Isak W. Tengesdal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression
- (2021) Isak W. Tengesdal et al. Frontiers in Immunology
- Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
- (2020) Caroline Bergenfelz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
- (2020) Andrew M. K. Law et al. Cells
- A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy
- (2020) Balamayoora Theivanthiran et al. JOURNAL OF CLINICAL INVESTIGATION
- NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway
- (2020) Qiao Zheng et al. BIOSCIENCE REPORTS
- PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer
- (2020) Wendan Yu et al. Cell Death & Disease
- IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
- (2019) Alexander Thiem et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PD‑L1 expression levels on tumor cells affect their immunosuppressive activity
- (2019) Yang Zheng et al. Oncology Letters
- NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis
- (2019) Nour Ershaid et al. Nature Communications
- Mechanisms regulating PD-L1 expression on tumor and immune cells
- (2019) Shuming Chen et al. Journal for ImmunoTherapy of Cancer
- IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer
- (2018) Te-Chia Wu et al. CANCER RESEARCH
- OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
- (2018) Carlo Marchetti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
- (2018) Jiawen Qian et al. Journal of Neuroinflammation
- Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation
- (2018) Irena Kaplanov et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression of checkpoint molecules on myeloid-derived suppressor cells
- (2017) Marlene Ballbach et al. IMMUNOLOGY LETTERS
- The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
- (2017) Xiaodong Feng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
- (2017) Kenji Gonda et al. Oncology Letters
- P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer
- (2017) Ju Young Bae et al. Oncotarget
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Prognostic Significance of Preoperative Circulating Monocyte Count in Patients With Breast Cancer
- (2015) Jiahuai Wen et al. MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity
- (2014) Y. Cao et al. CANCER RESEARCH
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
- (2012) Jaclyn Sceneay et al. OncoImmunology
- IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function
- (2010) Moshe Elkabets et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interleukin-1β promotes the expression of monocyte chemoattractant protein-1 in human aorta smooth muscle cells via multiple signaling pathways
- (2009) Jun Hee Lim et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1β
- (2009) Miyako Okamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started